We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Macrophage Role in Infection Determined by PI-3 Kinase-Gamma Signaling

By LabMedica International staff writers
Posted on 29 Sep 2016
Cancer researchers have identified a molecule responsible for the signal that converts macrophages from an inflammatory, immunostimulatory mode in acute infections to an anti-inflammatory, immunosuppressive mode that supports tumor development and growth.

Macrophages play critical, but opposite, roles in acute and chronic inflammation and cancer. More...
In response to pathogens or injury, inflammatory macrophages express cytokines that stimulate cytotoxic T-cells, while highly abundant macrophages in cancer and parasitic diseases express anti-inflammatory cytokines that induce immune suppression and may promote tumor growth.

Investigators at the University of California, San Diego (USA) reported in the September 19, 2016, online issue of the journal Nature that results of experiments carried out with mouse models had allowed them to identify the macrophage enzyme PI-3 kinase-gamma (PI3K-gamma) as the controller of a critical switch between immune stimulation and suppression during inflammation and cancer.

PI3K-gamma signaling induced a transcriptional program that promoted immune suppression during inflammation and tumor growth. In contrast, selective inactivation of macrophage PI3K-gamma promoted an immunostimulatory transcriptional program that restored CD8+ T-cell activation and cytotoxicity and synergized with checkpoint inhibitor therapy to promote tumor regression and extend survival in mouse models of cancer.

“Immunotherapies, such as T-cell checkpoint inhibitors, are showing great promise in early treatments and trials, but they are not universally effective,” said senior author Dr. Judith A. Varner, professor of pathology and medicine at the University of California, San Diego. “We have identified a new method to boost the effectiveness of current immune therapy. Our findings also improve our understanding of key mechanisms that control cancer immune suppression and could lead to the development of more effective immunotherapies.”

Related Links:
University of California, San Diego


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.